Sangamo exec granted 225,000 stock options
Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant. The award covers 225,000 stock options for common shares at an exercise price of $0.2601 per share, expiring on March 31, 2036.
One-quarter of the options will vest on the first anniversary of the grant, with the remaining options vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan. After this grant, he holds 225,000 derivative securities directly.
Insider Trade Summary
Grant/Award: 225,000 shares
Grant/Award
1 txn
Insider
Davis Gregory D
Role
Head of Research & Technology
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 225,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 225,000 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 225,000 contracts (Direct)
Footnotes (1)
- F1. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Key Figures
Options Granted: 225,000 options
Exercise Price: $0.2601 per share
Expiration Date: March 31, 2036
+1 more
4 metrics
Options Granted
225,000 options
Stock option award to Gregory D. Davis
Exercise Price
$0.2601 per share
Strike price for newly granted options
Expiration Date
March 31, 2036
Option term end for this grant
Derivative Holdings After Grant
225,000 derivative securities
Total options held following this transaction
Key Terms
Stock Option (Right to Buy), exercise price, Continuous Service, 2018 EIP, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "0.2601""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Continuous Service financial
"subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP)"
2018 EIP financial
"subject to acceleration as provided in the 2018 EIP"
vest financial
"shares subject to the option will vest and become exercisable"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sangamo Therapeutics (SGMO) report for Gregory D. Davis?
Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a grant of 225,000 stock options. These options give him the right to buy common shares at a fixed exercise price if vesting and service conditions are met over time.
How many Sangamo Therapeutics (SGMO) stock options were granted to Gregory D. Davis?
Gregory D. Davis was granted 225,000 stock options linked to Sangamo Therapeutics common stock. Each option represents the right to purchase one share, subject to vesting conditions and an exercise price specified in the equity incentive plan documentation.
What is the exercise price of Gregory D. Davis’s new Sangamo (SGMO) stock options?
The new stock options granted to Gregory D. Davis have an exercise price of $0.2601 per share. This means he can later buy Sangamo common shares at $0.2601 if the options vest and he chooses to exercise before the stated expiration date.
When do the newly granted Sangamo (SGMO) options to Gregory D. Davis expire?
The stock options granted to Gregory D. Davis expire on March 31, 2036. He must satisfy the vesting schedule and exercise the options before that date; otherwise, any unexercised vested options will lapse at expiration under the plan terms.
How do Gregory D. Davis’s Sangamo (SGMO) options vest over time?
One-quarter of the options vest and become exercisable on the first anniversary of the grant date. The remaining options vest in 24 equal monthly installments, contingent on his continuous service under Sangamo’s 2018 Equity Incentive Plan and any acceleration provisions in that plan.
Is Gregory D. Davis’s Sangamo (SGMO) stock option grant an open-market purchase?
No, the transaction is classified as a grant or award acquisition, not an open-market purchase. The Form 4 uses transaction code A for an option grant, reflecting compensation awarded by the company rather than shares bought directly in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
